
CORBUS P.H. NEW DL-,0001
Acción · US21833P3010 · CRBP · A3D54P (XNCM)
8,10 EUR
06.06.2025 20:15
Cotizaciones actuales de CORBUS P.H. NEW DL-,0001
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
CRBP
|
USD
|
06.06.2025 20:15
|
9,23 USD
| 8,85 USD
+4,29 %
|
![]() London |
0SZI.L
|
USD
|
06.06.2025 15:04
|
9,01 USD
| 8,85 USD
+1,81 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
-0,49 % | 25,53 % | 47,98 % | 29,23 % | -43,94 % | -80,17 % | -95,57 % |
Perfil de la empresa para CORBUS P.H. NEW DL-,0001 Acción
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Datos de la empresa
Nombre CORBUS P.H. NEW DL-,0001
Empresa Corbus Pharmaceuticals Holdings, Inc.
Símbolo CRBP
Sitio web
https://www.corbuspharma.com
Mercado principal
Frankfurt

WKN A3D54P
ISIN US21833P3010
Tipo de valor Acción
Sector Healthcare
Industria Medical - Pharmaceuticals
CEO Dr. Yuval Cohen Ph.D.
Capitalización de mercado 71 Mio
País Estados Unidos de América
Moneda EUR
Empleados 0,0 T
Dirección 500 River Ridge Drive, 02062 Norwood
Fecha de OPV 2018-11-23
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | 3371.F |
London | 0SZI.L |
NASDAQ | CRBP |
Otras acciones
Los inversores que tienen CORBUS P.H. NEW DL-,0001 también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.